OSLO, Norway, Nov. 1, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2018 results. Targovax's management will host an online presentation for...
from PR Newswire: //https://ift.tt/2yLVE7Y
No comments:
Post a Comment